Galapagos

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAP

ADTX

AREB

ATMV

BYND

CYCU

DCGO

GLPG

GSIT

HTCR

IBIO

JWEL

KXIN

NEUP

RYOJ

SONM

TBPH

El premercado muestra fuertes movimientos tras resultados mixtos, con CCK liderando las subidas y varios valores biotecnológicos en caída.

Acciones de Crown Holdings (CCK) suben un 9%; Aquí están 20 acciones que se mueven en el premercado

Galapagos NV - American Depositary Shares

Galapagos NV

Press Releases

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Galapagos Creates New Subscription Right Plan

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

Beam Therapeutics

Biohaven

Cidara Therapeutics

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Cogent Biosciences

Denali Therapeutics

ImmunityBio

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Janux Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

MannKind

NuCana

uniQure

Arcus Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Sionna Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Spyre Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

RBC Capital

Leerink Partners

Morgan Stanley

B of A Securities

Comments

Galapagos

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL